Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

AI gets access to big novel chemistry space for quick and effective drug discovery

San Diego (CA) - Insilico

Medicine, in collaboration with ChemDiv, Inc., launched a drug discovery

initiative that aims to use the power of artificial intelligence for screening

chemistry space with newly designed compounds. The

initiative is expected to identify a massive of 

drug candidates in early stages. That became possible because AI can

scan a vast number of compounds at higher speeds and with improved accuracy

compared to traditional screening projects. The new

project is aimed at rapidly screening targets in various therapeutic areas,

including oncology, metabolism, immunology, urology and others.

“We have

successfully identified early drug candidates by screening a limited number of

compounds with our AI virtual screening platform,” said Alex Zhavoronkov,

Ph.D., Founder and CEO of Insilico Medicine. “ChemDiv significantly increases

our capabilities by opening a great lead-like and drug-like novel chemical

space with reliable support. Our joint effort to evaluate these diverse

compounds increases the likelihood of developing new drugs for existing targets

with less adverse effects.”

“We are connecting AI technology with ChemDiv's efforts and investments in the design and validation of novel chemistry,” said Sergey Bugrov, Executive Director, ChemDiv. “The feasible chemical space of 3 billion molecules  partitioned in validated unique scaffolds and available for modeling is represented  by 1.7 million physical compounds. This new approach, will immediately provide researchers with many more starting points for drug discovery and significantly improve  their  process”.

About ChemDiv

ChemDiv is a recognized global leader in drug discovery

solutions. Over the past 29 years ChemDiv has delivered hundreds of leads, drug

candidates and new drugs in the area of CNS, oncology, virology, inflammation,

cardiometabolic and immunology, to pharma, biotech and academic partners around

the globe. [www.chemdiv.com]

About Insilico Medicine


Medicine is an artificial intelligence company headquartered in Hong Kong, with

offices in six countries and regions. The Company was the first to apply the

generative adversarial networks (GANs) and reinforcement learning (RL) to

generate new molecular structures with the specified parameters in 2015. In

addition to collaborating with large pharmaceutical companies, Insilico

Medicine is also pursuing internal drug discovery programs in different disease

areas and anti-aging fields. Recently, Insilico Medicine published some of the

resuts in Nature Biotechnology, and

secured $37 million in series B funding. Website http://insilico.com/

Media Contacts

For further information, images or interviews, please contact:

Insilico Medicine: Klug Gehilfe, ai@insilico.com

ChemDiv Inc.: Ron Demuth,  rd@chemdiv.com

0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies